Ultrasmall nanoparticles for co-delivery of antisense oligonucleotides targeting miR-21 and miR-210 to treat glioblastoma.

ABSTRACT: Glioblastoma (GBM) is the most common and aggressive type of brain tumour, with less than 5% of patients surviving more than 5 years. Despite decades of research to understand the underlying pathophysiological causes, it has witnessed very slow progress in terms of clinical translation of therapies. This is partially due to the lack of effective delivery strategies for overcoming major obstacles such as blood-brain barrier (BBB) and blood tumour barrier (BTB). Out of the pool of the oncogenic microRNAs, miR-21 and miR-210 are known to regulate several hallmarks of GBM tumorigenesis. Targeting these dysregulated microRNAs using antisense oligonucleotides has a huge therapeutic potential for GBM therapy. However, such microRNAs cannot be delivered without an effective delivery system, which

SUBMITTER: Singh RR 

PROVIDER: S-EPMC12225093 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature